Kadmon Holdings Inc (KDMN) Expected to Post Quarterly Sales of $340,000.00

Wall Street analysts expect Kadmon Holdings Inc (NYSE:KDMN) to announce $340,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kadmon’s earnings, with estimates ranging from $200,000.00 to $480,000.00. Kadmon reported sales of $430,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 20.9%. The firm is expected to issue its next quarterly earnings report on Tuesday, April 2nd.

On average, analysts expect that Kadmon will report full year sales of $3.87 million for the current fiscal year, with estimates ranging from $1.54 million to $6.20 million. For the next fiscal year, analysts forecast that the firm will post sales of $27.68 million, with estimates ranging from $16.80 million to $38.56 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Kadmon.

Kadmon (NYSE:KDMN) last posted its earnings results on Thursday, March 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.18). Kadmon had a negative net margin of 3,848.01% and a negative return on equity of 192.20%.

Several equities analysts recently issued reports on KDMN shares. Zacks Investment Research upgraded shares of Kadmon from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Friday, February 22nd. ValuEngine lowered shares of Kadmon from a “buy” rating to a “hold” rating in a report on Friday, December 21st. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Kadmon in a report on Tuesday, March 12th. Finally, Citigroup raised shares of Kadmon from a “neutral” rating to a “buy” rating and set a $2.77 price target for the company in a report on Tuesday, February 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Kadmon has an average rating of “Hold” and a consensus target price of $8.36.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its holdings in Kadmon by 46.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 290,478 shares of the company’s stock worth $970,000 after acquiring an additional 92,415 shares in the last quarter. Virtus ETF Advisers LLC purchased a new stake in shares of Kadmon during the fourth quarter worth $286,000. Fosun International Ltd purchased a new stake in shares of Kadmon during the fourth quarter worth $335,000. BlackRock Inc. grew its holdings in shares of Kadmon by 42.1% during the third quarter. BlackRock Inc. now owns 6,768,569 shares of the company’s stock worth $22,606,000 after buying an additional 2,005,133 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Kadmon by 29.2% during the third quarter. Renaissance Technologies LLC now owns 332,233 shares of the company’s stock worth $1,110,000 after buying an additional 75,033 shares in the last quarter. 64.14% of the stock is owned by institutional investors.

Shares of KDMN traded up $0.13 during trading hours on Wednesday, hitting $2.77. The stock had a trading volume of 970,172 shares, compared to its average volume of 953,171. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.12 and a quick ratio of 4.08. Kadmon has a fifty-two week low of $1.88 and a fifty-two week high of $4.46. The stock has a market cap of $335.04 million, a P/E ratio of -1.95 and a beta of 2.80.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Further Reading: Why does the United States have a lingering trade deficit?

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.